3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Active not recruiting
4
Recruiting
3
Completed
3
Suspended
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Neoplasms
3
Colorectal Neoplasms
3
Thyroid Neoplasms
2
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Multiple Myeloma
1
Melanoma
1
Lymphoproliferative Disorders
1
Laryngeal Neoplasms
1
Histiocytosis, Langerhans-Cell
1
Hematologic Neoplasms
1
Glioma
1
Gastrointestinal Neoplasms
1
Erdheim-Chester Disease
1
Ameloblastoma
1
Interventions
Temozolomide
4
vorasidenib
2
Lomustine
2
Blood Specimen Collection
2
trametinib
1
tovorafenib
1
posaconazole
1
perillyl alcohol
1
pembrolizumab
1
niraparib
1
mirdametinib
1
gallium maltolate
1
dabrafenib
1
cemiplimab
1
Urination
1
Transurethral Resection of Bladder
1
Standard of Care
1
Spinal Puncture
1
Specimen Handling
1
Sitagliptin Phosphate
1
Receptors, Interleukin-8B
1
Radiotherapy
1
Radiation
1
Positron Emission Tomography Computed Tomography
1
Physical Therapy Modalities
1
Mental Status and Dementia Tests
1
Magnetic Resonance Spectroscopy
1
Magnetic Resonance Imaging
1
Ketoconazole
1
Histocompatibility Testing
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Glioma
×
trametinib
×
Clear all
NCT07440290
2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3
Not yet recruiting
30 enrolled